We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Oxurion Nv | LSE:0G99 | London | Ordinary Share | BE0974487192 | OXURION NV ORD SHS |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 48,800.00 | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 154k | -18.97M | -0.0054 | -50.00 | 170.29T |
From Jun 2024 to Dec 2024
Oxurion Announces Results on the Extraordinary General Meeting (EGM) of 24 July 2024
Leuven, BELGIUM – 24 July, 2024 – 06.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, held an Extraordinary General Meeting on July 24, 2024. The shareholders approved all items on the agenda of the Extraordinary General Meeting.
All documents pertaining to the Extraordinary General Meeting held on July 24, 2024, can be consulted on Oxurion’s website Oxurion/shareholders.
About Oxurion
Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com.
Please contact for additional information:
| Oxurion NV Pascal Ghoson Chief Executive Officer pascal.ghoson@oxurion.com |
Attachments
1 Year Oxurion Nv Chart |
1 Month Oxurion Nv Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
